Coherus Oncology, Inc. (CHRS) Stock Grade

About Coherus Oncology, Inc.'s fundamentals

Coherus Oncology is a small-cap biotechnology company with a market capitalization of $170.9M that reported severe operational challenges in its latest fiscal year. The company experienced an 84.2% year-over-year revenue decline and posted a net loss with a negative net margin of -403.8%, indicating the company spent substantially more than it generated in revenue. With no dividend yield and unprofitable operations, the company is not currently generating shareholder returns from earnings.